| Not Yet Recruiting | A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cance Lung Cancer | N/A | 2026-04-30 |
| Not Yet Recruiting | CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma MZL | — | 2026-04-01 |
| Not Yet Recruiting | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma Indolent Lymphoma, WM, MZL | Phase 2 | 2026-03-10 |
| Not Yet Recruiting | Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cel DLBCL - Diffuse Large B Cell Lymphoma | — | 2026-03-10 |
| Not Yet Recruiting | Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer Breast Cancer | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Anlotinib in Cross-line Treatment of NSCLC and SCLC NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage | — | 2026-02-01 |
| Not Yet Recruiting | Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial Esophageal Cancer | Phase 3 | 2026-01-20 |
| Not Yet Recruiting | Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellula HCC - Hepatocellular Carcinoma | Phase 2 | 2026-01-05 |
| Not Yet Recruiting | Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Im Esophageal Cancer, Neoadjuvant Therapy | — | 2025-12-01 |
| Not Yet Recruiting | Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemother TNBC - Triple-Negative Breast Cancer | Phase 2 | 2025-11-26 |
| Recruiting | Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma Marginal Zone Lymphoma | — | 2025-11-18 |
| Not Yet Recruiting | SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer Advanced Breast Cancer | Phase 2 | 2025-09-30 |
| Recruiting | QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer Breast Cancer, HR+/HER2- Breast Cancer | Phase 2 | 2025-09-08 |
| Not Yet Recruiting | Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. Breast Cancer, HER2 + Breast Cancer | Phase 2 | 2025-09-01 |
| Recruiting | Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positiv HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy | Phase 2 | 2025-08-30 |
| Not Yet Recruiting | A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination Wit Resectable Stage II-IIIB NSCLC | Phase 2 | 2025-08-15 |
| Not Yet Recruiting | Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC Breast Cancer | Phase 2 | 2025-07-01 |
| Recruiting | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 Meningeal Metastasis | Phase 1 / Phase 2 | 2025-06-25 |
| Recruiting | Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer Breast Cancer | Phase 3 | 2025-06-24 |
| Not Yet Recruiting | SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer TNBC - Triple-Negative Breast Cancer | Phase 2 | 2025-06-23 |
| Recruiting | Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expan Breast Cancer Patients | — | 2025-05-20 |
| Not Yet Recruiting | The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Brea Advanced or Metastatic Breast Cancer | N/A | 2025-05-01 |
| Not Yet Recruiting | Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors Solid Tumors | Phase 1 / Phase 2 | 2025-05-01 |
| Recruiting | SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | 2025-04-16 |
| Recruiting | Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer HR+/HER2- Breast Cancer | Phase 2 | 2025-04-15 |
| Recruiting | A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR NSCLC | Phase 2 | 2025-04-02 |
| Not Yet Recruiting | Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pa Opioid-Induced Constipation, Pain Cancer | Phase 4 | 2025-04-01 |
| Active Not Recruiting | Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in th Esophageal Malignant Neoplasm Primary | Phase 2 | 2025-03-08 |
| Not Yet Recruiting | A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cance Breast Cancer, Locally Advanced or Metastatic Breast Cancer | Phase 1 / Phase 2 | 2025-03-01 |
| Not Yet Recruiting | Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Usin Esophageal Cancer, Neoadjuvant Therapy | — | 2025-03-01 |
| Recruiting | Organoid-guided Personalized Treatment of Pleural Effusion Lung Cancer | — | 2025-02-21 |
| Recruiting | Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment o Extensive-stage Small-cell Lung Cancer | — | 2025-02-20 |
| Not Yet Recruiting | Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MR Esophageal Cancer | — | 2025-02-01 |
| Not Yet Recruiting | Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure Non Small Cell Lung Cancer | — | 2025-02-01 |
| Not Yet Recruiting | Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia SCLC, Extensive Stage | Phase 2 | 2025-01-15 |
| Recruiting | Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia | Phase 2 | 2025-01-01 |
| Not Yet Recruiting | Application of LARS Ligament in Bone Prosthesis Replacement Malignant Tumor | — | 2024-12-30 |
| Not Yet Recruiting | Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors Malignant Tumor | — | 2024-12-28 |
| Unknown | Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy Malignant Tumor, Chemotherapy | N/A | 2024-12-28 |
| Not Yet Recruiting | Application of Antiosteoporosis Therapy in Osteolysis Limb; Fusion, Complication | — | 2024-12-28 |
| Unknown | Application of Douyin in Perioperative Period of Malignant Tumor Patients Malignant Tumor of Bone, Perioperative Period | N/A | 2024-12-28 |
| Recruiting | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metasta Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation | N/A | 2024-12-20 |
| Recruiting | NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. Breast Cancer Invasive | — | 2024-12-04 |
| Not Yet Recruiting | ARX788 in HER2-positive Metastatic Breast Cancer Patients HER2-positive, Metastatic Breast Cancer | Phase 2 | 2024-11-20 |
| Recruiting | Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC Triple-negative Breast Cancer | Phase 2 | 2024-11-06 |
| Not Yet Recruiting | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study Hepatocellular Carcinoma (HCC) | Phase 2 | 2024-11-01 |
| Recruiting | Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Breast Cancer Patients | N/A | 2024-10-30 |
| Not Yet Recruiting | Local Injection and Systemic Therapy in the Treatment of NSCLC. Non-small Cell Lung Cancer | Phase 2 | 2024-10-08 |
| Not Yet Recruiting | RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors KRAS G12V, T Cell Therapy | Phase 1 | 2024-08-01 |
| Not Yet Recruiting | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer NSCLC | Phase 1 / Phase 2 | 2024-08-01 |
| Not Yet Recruiting | Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngea Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms | Phase 2 | 2024-08-01 |
| Recruiting | A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of A Metastatic Breast Cancer | Phase 2 | 2024-06-19 |
| Not Yet Recruiting | Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADC Metastatic Breast Cancer in the Brain | Phase 2 | 2024-06-15 |
| Recruiting | L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma Relapsed/Refractory B-cell Lymphomas | Phase 1 | 2024-06-01 |
| Not Yet Recruiting | Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC NSCLC | Phase 2 | 2024-06-01 |
| Not Yet Recruiting | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly D Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin | Phase 2 | 2024-05-20 |
| Recruiting | Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer Sentinel Lymph Node Biopsy | — | 2024-04-30 |
| Active Not Recruiting | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer Breast Cancer | Phase 2 | 2024-04-28 |
| Recruiting | Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer Small Cell Lung Cancer | N/A | 2024-04-16 |
| Recruiting | Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Ca Non-small Cell Lung Cancer | N/A | 2024-04-16 |
| Enrolling By Invitation | the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib Non-small Cell Lung Cancer | Phase 2 | 2024-04-02 |
| Unknown | PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer Metastatic Colon Cancer | N/A | 2024-04-01 |
| Recruiting | Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Bi Unresectable Biliary Tract Carcinoma | Phase 2 | 2024-04-01 |
| Unknown | Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients HCC | Phase 2 | 2024-03-01 |
| Recruiting | RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors KRAS G12D, T Cell Therapy | Phase 1 | 2024-03-01 |
| Recruiting | An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small C Non-Small Cell Lung Cancer | EARLY_Phase 1 | 2024-02-28 |
| Recruiting | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2024-02-28 |
| Unknown | A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer SCLC,Extensive Stage | — | 2024-02-25 |
| Recruiting | TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer Colorectal Cancer | Phase 2 | 2024-02-23 |
| Recruiting | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanc Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma | Phase 1 / Phase 2 | 2024-02-22 |
| Not Yet Recruiting | Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cance Small Cell Lung Carcinoma | Phase 2 | 2024-02-10 |
| Unknown | Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With Gastric Cancer | Phase 2 | 2024-02-01 |
| Recruiting | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer Breast Cancer, HER2-positive Breast Cancer | Phase 2 | 2024-01-20 |
| Unknown | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Prolifera Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | 2024-01-19 |
| Recruiting | Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib Hepatocellular Carcinoma | N/A | 2024-01-15 |
| Recruiting | Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for H Advanced Breast Cancer, Treatment, HR Low/HER2 Negative | Phase 2 | 2024-01-01 |
| Unknown | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radi Extensive-stage Small-cell Lung Cancer | Phase 2 | 2023-12-01 |
| Unknown | The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) Non-hodgkin Lymphoma,B Cell | N/A | 2023-10-31 |
| Unknown | A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer Extensive Small Cell Lung Cancer | Phase 2 | 2023-10-16 |
| Recruiting | A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poo Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2023-09-12 |
| Recruiting | Go-CHOP as the Frontline Therapy for PTCL Peripheral T Cell Lymphoma | Phase 2 | 2023-08-03 |
| Recruiting | The Maintenance Treatment of "ITIVA" in AML Patients Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease | N/A | 2023-07-11 |
| Recruiting | A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer HER2 Low Breast Carcinoma | Phase 2 | 2023-07-05 |
| Completed | RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies Hematologic Malignancies | EARLY_Phase 1 | 2023-06-26 |
| Unknown | Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin Squamous Cell Carcinoma of the Skin | N/A | 2023-06-08 |
| Unknown | Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain Cancer Pain, Real-world Study, Oxycodone | — | 2023-06-01 |
| Not Yet Recruiting | Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma Peripheral T Cell Lymphoma | Phase 1 | 2023-05-30 |
| Recruiting | Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors Malignant Tumor, Anxiety, Depression | — | 2023-05-20 |
| Unknown | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatme Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | 2023-05-08 |
| Recruiting | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC Breast Cancer, HER2-positive Breast Cancer | Phase 2 | 2023-05-03 |
| Recruiting | Lenvatinib for Advanced Bone and Soft Tissue Sarcoma Effectiveness, Sexuality | Phase 2 | 2023-04-30 |
| Recruiting | To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Pat Locally Advanced Breast Cancer | — | 2023-04-04 |
| Recruiting | Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases Metastatic Breast Cancer | Phase 2 | 2023-03-31 |
| Unknown | Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma Soft Tissue Sarcoma | N/A | 2023-03-20 |
| Unknown | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Loc Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | 2023-01-01 |
| Unknown | PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma Advanced Melanoma | Phase 2 | 2022-12-30 |
| Unknown | Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer Hydroxychloroquine, Gemcitabine, Lung Neoplasms | Phase 2 | 2022-12-15 |
| Unknown | Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of A Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited | Phase 1 | 2022-12-01 |
| Unknown | Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recur Hepatocellular Carcinoma | Phase 2 | 2022-11-01 |
| Completed | A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanc Breast Cancer | Phase 2 | 2022-09-21 |
| Unknown | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Canc NSCLC | — | 2022-09-21 |
| Unknown | Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor Desmoid | N/A | 2022-08-20 |
| Recruiting | Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer HER-2 Negative Breast Cancer | Phase 2 | 2022-08-19 |
| Unknown | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Squamous Cell Carcinoma of the Skin | Phase 2 | 2022-08-05 |
| Recruiting | Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors Bone and Soft Tissue Tumors, Clinical Features | — | 2022-08-03 |
| Recruiting | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 3 | 2022-08-01 |
| Unknown | A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients Early Gastric Cancer, Tumor Organoids | — | 2022-08-01 |
| Recruiting | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 2 | 2022-07-26 |
| Unknown | Study on Clinical Features, Treatment Mode and Survival of Sarcoma Sarcoma | — | 2022-06-07 |
| Unknown | Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications, Intraoperative Complications | N/A | 2022-06-06 |
| Unknown | Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERME Breast Cancer | — | 2022-05-30 |
| Unknown | Camrelizumab Combined With Apatinib Mesylate Solid Tumor | N/A | 2022-05-20 |
| Unknown | Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-He Breast Neoplasms | Phase 2 | 2022-05-20 |
| Active Not Recruiting | Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer Gastric Cancer | Phase 2 | 2022-05-13 |
| Unknown | Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure HR Positive HER2 Negative Advanced Breast Cancer | Phase 1 / Phase 2 | 2022-05-13 |
| Withdrawn | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Canc Breast Cancer, HER2-positive Breast Cancer | Phase 3 | 2022-05-11 |
| Unknown | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer Advanced Gastric Carcinoma, HER2-positive Gastric Cancer | Phase 2 | 2022-05-07 |
| Unknown | Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases Breast Cancer | Phase 2 | 2022-04-29 |
| Unknown | A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Advanced Gastric Adenocarcinoma | N/A | 2022-03-31 |
| Unknown | Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer Breast Cancer | Phase 2 | 2022-03-22 |
| Unknown | Cryoablation for Advanced Bone and Soft Tissue Tumors Sarcoma, Cryoablation | — | 2022-03-10 |
| Unknown | An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in Non-small Cell Lung Cancer | Phase 2 | 2022-02-20 |
| Terminated | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Peripheral T-Cell Lymphoma | Phase 1 | 2022-02-20 |
| Completed | Anti-emetic Prophylaxis With or Without Dexamethasone Chemotherapy-induced Nausea and Vomiting | Phase 3 | 2022-02-01 |
| Unknown | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholang Cholangiocarcinoma | Phase 2 | 2022-01-01 |
| Unknown | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. Soft Tissue Sarcoma | Phase 2 | 2022-01-01 |
| Unknown | Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepa Recurrent Hepatocellular Cancer | N/A | 2022-01-01 |
| Recruiting | Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma Central Nervous System Lymphoma | Phase 2 | 2021-12-21 |
| Terminated | Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Ca Metastatic Breast Cancer | Phase 1 / Phase 2 | 2021-12-08 |
| Completed | Application of Painting Analysis and Psychotherapy in Children With Bone Tumors Bone Tumors | N/A | 2021-10-20 |
| Recruiting | Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer Breast Cancer | Phase 3 | 2021-09-28 |
| Unknown | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer SCLC, Extensive Stage | Phase 2 | 2021-09-05 |
| Unknown | TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cance Esophageal Neoplasms | Phase 2 | 2021-09-01 |
| Unknown | Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer Metastatic Colorectal Cancer | — | 2021-07-20 |
| Unknown | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer Small Cell Lung Carcinoma | Phase 2 | 2021-07-14 |
| Unknown | Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy Surgery--Complications | N/A | 2021-07-01 |
| Recruiting | Toripalimab Plus FLOT in Locally Advanced Gastric Cancer Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma | Phase 2 | 2021-06-25 |
| Unknown | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance Central Nervous System Lymphoma | Phase 2 | 2021-05-26 |
| Completed | Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer SCLC, Extensive Stage | Phase 2 | 2021-05-20 |
| Active Not Recruiting | TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Ade Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | N/A | 2021-05-10 |
| Unknown | Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma Soft Tissue Sarcoma | N/A | 2021-04-29 |
| Unknown | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma Advanced Gastric Carcinoma | Phase 2 | 2021-04-28 |
| Unknown | Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treat HER2 Positive Metastatic Breast Cancer | Phase 2 | 2021-04-23 |
| Unknown | A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTIST NSCLC, Brain Metastases, Leptomeningeal Metastasis | N/A | 2021-03-20 |
| Recruiting | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphom Primary Central Nervous System Lymphoma | Phase 2 | 2021-01-13 |
| Completed | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | 2021-01-04 |
| Completed | Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma Esophagus Cancer | — | 2021-01-01 |
| Suspended | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymph Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation | Phase 2 | 2020-12-25 |
| Unknown | A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors Digestive System Tumors | Phase 1 | 2020-11-14 |
| Recruiting | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer Breast Cancer,HER2-positive | Phase 3 | 2020-09-18 |
| Withdrawn | GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel Early Breast Cancer | Phase 2 | 2020-09-09 |
| Completed | A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity Early Breast Cancer | Phase 2 | 2020-08-28 |
| Unknown | Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer Advanced Gastric Adenocarcinoma | N/A | 2020-08-17 |
| Completed | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma Marginal Zone Lymphoma | Phase 2 | 2020-04-22 |
| Recruiting | Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma Esophageal Cancer, Surgery, Neoadjuvant Treatment | Phase 3 | 2020-04-21 |
| Withdrawn | Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Pati Stage IV Breast Cancer | Phase 2 | 2020-04-15 |
| Unknown | L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy Advanced Solid Tumor | — | 2020-04-02 |
| Unknown | Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC Non-small Cell Lung Cancer Metastatic | Phase 4 | 2020-04-01 |
| Unknown | Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer Metastatic Breast Cancer | Phase 2 | 2020-04-01 |
| Active Not Recruiting | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarc Gastric Cancer | Phase 2 | 2020-01-20 |
| Completed | R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma | Phase 2 | 2020-01-05 |
| Unknown | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 2 | 2020-01-01 |
| Unknown | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer Triple-negative Breast Cancer | Phase 1 / Phase 2 | 2020-01-01 |
| Unknown | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for NSCLC | Phase 1 / Phase 2 | 2019-12-01 |
| Recruiting | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cance Esophageal Squamous Cell Carcinoma | Phase 3 | 2019-10-22 |
| Unknown | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal S Esophageal Squamous Cell Carcinoma | Phase 2 | 2019-10-07 |
| Completed | Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC Extensive Disease Small Cell Lung Cancer | Phase 2 | 2019-09-11 |
| Unknown | An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment Cancer | Phase 1 | 2019-09-04 |
| Unknown | Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer Ovarian Cancer | Phase 2 | 2019-09-01 |
| Unknown | Study of CT and MR in the Gastric Cancer Gastric Cancer Stage, CT, MRI | — | 2019-09-01 |
| Unknown | Study of CT and MR in the Lung Cancer Lung Cancer Squamous Cell, CT, Genes | — | 2019-09-01 |
| Active Not Recruiting | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymp Classical Hodgkin Lymphoma | Phase 2 | 2019-08-26 |
| Unknown | PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma Gastric and Esophagogastric Junction Adenocarcinoma | Phase 2 | 2019-07-30 |
| Unknown | Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional A Gastric Cancer | Phase 2 | 2019-07-24 |
| Unknown | Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer Squamous Cell Carcinoma, Esophageal Cancer, Perioperative Period | Phase 2 | 2019-07-10 |
| Completed | Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Soft Tissue Sarcomas | Phase 4 | 2019-06-26 |
| Unknown | Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer Small Cell Lung Cancer, Extensive Disease, Adoptive Cellular Immunotherapy | Phase 2 | 2019-06-20 |
| Unknown | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma Mucosal Melanoma, Advanced Cancer, Apatinib | Phase 2 | 2019-06-04 |
| Unknown | Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer Advanced Gastric Cancer | Phase 2 | 2019-06-01 |
| Unknown | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 T Gastrointestinal Neuroendocrine Tumor | Phase 2 | 2019-06-01 |
| Unknown | Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol Advanced Gastrointestinal Tumors | N/A | 2019-06-01 |
| Unknown | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast HER2 Positive Breast Cancer | N/A | 2019-06-01 |
| Unknown | Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd- Advanced Solid Tumor | Phase 2 / Phase 3 | 2019-04-08 |
| Unknown | Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC Non-squamous Cell Non-Small Cell Lung Cancer | Phase 1 | 2019-03-22 |
| Unknown | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies Refractory, Relapsed, B Cell Lymphoma | Phase 1 | 2019-02-27 |
| Unknown | SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer Small Cell Lung Cancer Extensive Stage | Phase 2 | 2019-02-01 |
| Unknown | CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma B-Cell Lymphoma Stage I, Refractory, Relapsed | Phase 1 | 2019-02-01 |
| Recruiting | Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma, Gene Abnormality | — | 2019-01-03 |
| Completed | Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC Triple Negative Breast Cancer | Phase 2 | 2018-11-23 |
| Unknown | A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast HER2 Positive Metastatic Breast Cancer | Phase 2 | 2018-11-20 |
| Unknown | A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma Gastric Carcinoma | — | 2018-11-20 |
| Completed | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer P HER2 Positive Breast Cancer | Phase 2 | 2018-11-20 |
| Unknown | the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets i Tumor, Chemotherapy-induced Nausea and Vomiting | Phase 2 | 2018-09-07 |
| Unknown | The Application of 3T MRI in Esophageal Cancer Esophageal Cancer TNM Staging, Magnetic Resonance Imaging, Prognosis | — | 2018-09-02 |
| Unknown | Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma Relapsed Non Hodgkin Lymphoma | Phase 1 | 2018-04-12 |
| Unknown | BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma Relapsed/Refractory Myeloma | Phase 1 | 2018-04-11 |
| Unknown | S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous Advanced NSCLC With EGFR Mutation | Phase 2 | 2018-03-28 |
| Unknown | The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal Adenocarcinoma of the Stomach / Gastroesophageal | Phase 2 | 2018-02-05 |
| Completed | Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma Esophageal Cancer | Phase 4 | 2018-01-31 |
| Unknown | Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer Colorectal Cancer | Phase 2 | 2018-01-09 |
| Unknown | An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer Esophageal Cancer | — | 2017-12-12 |
| Unknown | Study of BCMA CAR-T in Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2017-12-08 |
| Unknown | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2017-11-29 |
| Unknown | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma Malignant Melanoma | Phase 2 | 2017-11-29 |
| Unknown | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Lung Adenocarcinoma | Phase 2 | 2017-10-12 |
| Unknown | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. B-cell Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | 2017-08-16 |
| Unknown | A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Abo Head and Neck Squamous Cell Carcinoma | Phase 2 | 2017-07-05 |
| Unknown | Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, On Osteosarcoma, Advanced | Phase 2 | 2017-04-11 |
| Withdrawn | Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Canc Esophageal Cancer, Lung Cancer, Hyperthermic Perfusion | N/A | 2017-03-21 |
| Unknown | Apatinib Treatment for Advanced Esophagus Cancer Advanced Esophagus Cancer | Phase 2 | 2017-02-21 |
| Terminated | Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer Advanced Cancer | Phase 2 | 2016-11-01 |
| Unknown | The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma B Cell Lymphoma | Phase 1 | 2016-08-01 |
| Unknown | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). B-cell Acute Lymphoblastic Leukemia | Phase 1 | 2016-07-18 |
| Completed | Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastat Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer | — | 2016-07-01 |
| Unknown | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma Diffuse Large B-cell Lymphoma | Phase 2 | 2016-05-01 |
| Unknown | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation Lung Adenocarcinoma | Phase 2 | 2016-04-13 |
| Unknown | The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province Gastric Cancer | — | 2016-01-30 |
| Terminated | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarc Lung Adenocarcinoma | Phase 2 | 2015-10-01 |
| Completed | Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Esophageal Neoplasm | Phase 3 | 2015-06-01 |